Cagrilintide is an experimental, unapproved drug, injected once weekly, that copies amylin, a meal-ending hormone from the pancreas, to control weight. On its own it produces meaningful, well-replicated weight loss in adults with excess weight; smaller effects on blood pressure and, in diabetes, blood sugar are reasonably supported. Side effects are mostly stomach-related. Evidence is short-term and almost entirely company-funded; no study has tested whether it extends healthy life. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percentage change from own baseline | Main expected effect |
| Blood pressure | Below 120/80 mm Hg | Expected to change; safety check for low pressure |
| HbA1c | 4.0–5.6% | Expected to change in diabetes or prediabetes |
| Fasting glucose | 70–99 mg/dL | Safety check for hypoglycemia with insulin or sulfonylureas |
| eGFR | 60 mL/min/1.73 m² or higher | Safety check for dehydration from vomiting or diarrhea |
| Lean mass by DXA | No established target; track change from own baseline | Safety check for muscle loss |
Cadence: Baseline before starting; at 4, 8, 12 and 16 weeks during titration, then every 3 months for the first year and every 6–12 months thereafter. Weight and blood pressure weekly at home during titration. HbA1c and kidney function every 3 months with diabetes, otherwise every 6–12 months. Repeat body-composition scan after 6–12 months.